Aug 12, 2026 07:59AM
Aug 12, 2026 07:23AM
Aug 11, 2026 04:01PM
Aug 11, 2026 04:01PM
Jul 20, 2026 08:00AM
Jul 20, 2026 08:00AM
Jun 16, 2026 06:44AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
Jun 15, 2026 03:02AM
Jun 12, 2026 09:30PM
May 22, 2026 09:33AM
May 21, 2026 06:38AM
May 20, 2026 06:00AM
May 18, 2026 04:00PM
May 18, 2026 04:00PM Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
May 15, 2026 08:00AM
Apr 27, 2026 08:00AM
Apr 22, 2026 08:35AM
Apr 21, 2026 04:00PM
Apr 21, 2026 04:00PM
Apr 13, 2026 06:38AM
Apr 7, 2026 07:46AM Belite Bio ADR (BLTE) Reiterated at Buy by Benchmark After Model Update
Mar 4, 2026 08:42AM
Mar 4, 2026 06:42AM
Mar 3, 2026 09:37AM
Mar 2, 2026 06:00AM
Jan 29, 2026 08:00AM
Jan 27, 2026 08:04AM
Jan 27, 2026 08:00AM Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
Jan 26, 2026 06:12AM
Dec 3, 2025 08:44AM
Dec 1, 2025 06:00AM
Dec 1, 2025 06:00AM
Nov 10, 2025 08:00AM
Sep 15, 2025 07:28AM
Sep 10, 2025 08:51AM Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE) Following PIPE Transaction
Aug 12, 2025 09:42AM
Aug 11, 2025 06:00AM
Jul 2, 2025 03:00AM
May 22, 2025 08:39AM
May 21, 2025 03:00AM
May 15, 2025 09:10AM
May 15, 2025 07:23AM Cantor Fitzgerald Reiterates Overweight Rating on Belite Bio, Inc, ADR (BLTE)
May 13, 2025 09:00PM
Apr 29, 2025 08:00AM
Mar 17, 2025 06:00AM
Nov 27, 2024 03:00AM
Nov 12, 2024 01:00AM
Oct 14, 2024 08:00AM
Sep 10, 2024 08:00AM Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
Aug 9, 2024 04:30PM

328,234 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All